Adam M. Brufsky, MD, PhD

Dr Brufsky discusses the FDA approval of gedatolisib plus fulvestrant ± palbociclib for hormone receptor–positive, PIK3CA wild-type advanced breast cancer.

Adam M. Brufsky, MD, PhD, discusses the FDA approval of gedatolisib/fulvestrant/palbociclib for PIK3CA wild-type hormone receptor–positive breast cancer.

Dr. Adam Brufsky concludes the discussion by asking the panel to reflect on the most significant unmet needs in the management of HR-positive/HER2-negative metastatic breast cancer and the future direction of the field.

Dr. Adam Brufsky and the panel conclude the program by exploring future treatment considerations in HR-positive/HER2-negative metastatic breast cancer, including the expanding number of available oral SERDs and the factors that may influence treatment selection.

Dr. Adam Brufsky and the panel conclude their discussion by examining the increasingly complex treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer who experience recurrence after receiving modern adjuvant therapies.

Dr. Adam Brufsky and the panel shift their focus to early-stage HR-positive/HER2-negative breast cancer and discuss emerging endocrine therapy strategies that may influence future treatment paradigms.

Dr. Adam Brufsky and the panel continue their discussion of oral SERDs in HR-positive/HER2-negative metastatic breast cancer, focusing on how emerging clinical data may influence treatment sequencing after progression on CDK4/6 inhibitor-based therapy.

Dr. Adam Brufsky leads a discussion on one of the most debated topics in HR-positive/HER2-negative metastatic breast cancer: the use of oral SERDs and the potential role of molecular monitoring to guide treatment changes before radiographic progression.

Dr. Adam Brufsky and the panel transition to a discussion of oral selective estrogen receptor degraders (SERDs) and their evolving role in the management of HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky and the panel continue their discussion of treatment sequencing in HR-positive/HER2-negative metastatic breast cancer, focusing on the role of molecular profiling and biomarker-directed therapy following progression on CDK4/6 inhibitor-based treatment.

Dr. Adam Brufsky and the panel examine treatment decision-making following progression on first-line CDK4/6 inhibitor-based therapy in patients with HR-positive/HER2-negative metastatic breast cancer.

Dr. Adam Brufsky and the panel discuss the practical implementation of PI3K-directed triplet therapy in patients with HR-positive/HER2-negative metastatic breast cancer, focusing on treatment selection, sequencing considerations, and toxicity management.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky leads a discussion on the evolving role of triplet therapy in HR-positive/HER2-negative metastatic breast cancer, focusing on the clinical implications of the INAVO-120 study and how its findings may influence treatment selection.

Dr. Adam Brufsky opens the discussion by introducing the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer.

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Medical experts address the challenges of managing adverse events in the treatment of HR+/HER2- locally advanced or metastatic breast cancer.

Key opinion leaders discuss other clinical trials, including the EMERALD study, and targeted therapies for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in later lines of therapy.

Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.

Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.